**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | ASH DCU | **Project Code** | PI4VDU109 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Chelsey/Briana |
| **Compliance** | Briana Devaser | **Editor** | Heather/Christi |

**Launch Date/Internal Launch Date:**

72 hours post filming

**Project Type**

Video

Downloadable Slides

Other:

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

Oncology Guru,

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

**CME?**

Yes

No

Webcast/PDS URL:

**www.primeoncology.org/2014\_sanfrancisco\_dcu**

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title: 2014 DCU San Francisco**

**Listing Page**

**[Insert small DCU Graphic to the left]**

**[TITLE]**

**Daily Clinical Updates: Up-to-Date Highlights from the 2014 Annual Hematology Meeting in San Francisco**

**[DATE** | **LOCATION]**

December 2014|San Francisco, California, United States

**Landing Page**

**[Insert DCU Graphic header]**

**LEFT SIDE**

**[Insert Text below]**

**Daily Clinical Updates: Up-to-Date Highlights from the 2014 Annual Hematology Meeting in San Francisco**

**Activity Features**

**[Insert icon]** Expert Discussion

**[Insert icon]** CME-Certified

**RIGHT SIDE**

**ACTIVITY OVERVIEW**

View CME-certified expert discussions regarding exciting news focusing on multiple myeloma, myelodysplastic syndromes, and non-Hodgkin lymphomareleased at the 2014 Annual Hematology Meeting in San Francisco.

**CONTINUING EDUCATION**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of X.XX *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**BOTTOM MIDDLE**

* Myelodysplastic Syndromes
* Multiple Myeloma: Front-Line
* Multiple Myeloma: Relapsed/Refractory
* Non-Hodgkin Lymphoma

**[Tab-MDS]**

Myelodysplastic Syndromes

Discussants: **Aristoteles Giagounidis, MD, PhD**, St Mary’s Hospital, Duesseldorf, Germany

**Elias Jabbour, MD,** The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Abstracts:

**Abstract #163:** Overall Survival and Subgroup Analysis From a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) After Failure of Hypomethylating Agents (HMAs)

**Abstract #409:** Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC Transfusion-Dependent Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) Without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results From a Randomized Phase 3 Study (CC-5013-MDS-005)

**Abstract #534:** Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients With Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy

**[Button] View**

**[Tab-MM FL]**

Multiple Myeloma: Front-Line

Discussants: **Kenneth Anderson, MD,** Dana-Farber Cancer Institute, Boston, Massachusetts, United States

**Jesus San Miguel, MD, PhD,** Universidad de Navarra, Pamplona, Spain

Featured Abstracts:

**Abstract #81:** Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The FIRST Trial

**Abstract #82:** Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) With Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

**Abstract #177:** Response to Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Newly Diagnosed Multiple Myeloma Is Independent of Cytogenetic Risk and Retained After Double Stem Cell Transplant

**Abstract #178:** Comparison of Sequential vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial

**[Button] View**

**[Tab-MM RR]**

Multiple Myeloma: Relapsed/Refractory

Discussants: **Sagar Lonial, MD,** Emory University, Winship Cancer Center, Atlanta, Georgia, United States

**Meletios Dimopoulos, MD,** University of Athens, Athens, Greece

Featured Abstracts:

**Abstract #79:** Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) With Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study

**Abstract #80:** Safety and Efficacy in the STRATUS (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

**Abstract #302:** Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

**Abstract #304:** Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients With Relapsed Lenalidomide Refractory Multiple Myeloma (MM)

**[Button] View**

**[Tab-NHL]**

Non-Hodgkin Lymphoma

Discussants: **Julie Vose, MD, MBA,** University of Nebraska Medical Center, Omaha, Nebraska, United States

**Myron Czuczman, MD,** Roswell Park Cancer Institute, Buffalo, New York, United States

Featured Abstracts:

**Abstract #149:** Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

**Abstract #393:** R-CHOP With or Without Radiotherapy in Non-Bulky Limited-Stage Diffuse Large B Cell Lymphoma (DLBCL): Preliminary Results of the Prospective Randomized Phase III 02-03 Trial From the Lysa/Goelams Group

**Abstract #625:** Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report

**Abstract #628:** A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL

**[Button] View**

**CME Information Pop-Up**

**Release Date**   
December X, 2014  
  
**Expiration Date**   
December X, 2015  
  
**Faculty**

**Kenneth Anderson, MD**

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

**Myron Czuczman, MD**

Roswell Park Cancer Institute

Buffalo, New York, United States

**Meletios Dimopoulos, MD**

University of Athens

Athens, Greece

**Aristoteles Giagounidis, MD, PhD**

St Mary’s Hospital

Duesseldorf, Germany

**Elias Jabbour, MD**

The University of Texas

MD Anderson Cancer Center

Houston, Texas, United States

**Sagar Lonial, MD**

Emory University

Winship Cancer Center

Atlanta, Georgia, United States

**Jesus San Miguel, MD, PhD**

Universidad de Navarra

Pamplona, Spain

**Julie Vose, MD, MBA**

University of Nebraska Medical Center

Omaha, Nebraska, United States

**Learning Objectives**  
After successful completion of this educational activity, participants should be able to:

* Evaluate recent findings from studies investigating biomarkers and molecular features of hematologic malignancies and disorders
* Apply emerging data from clinical trials evaluating novel agents and treatment approaches for hematologic malignancies and disorders
* Identify appropriate clinical trials and refer eligible patients with hematologic malignancies and disorders for enrollment to expand their treatment options

**Provider**  
This activity is provided by prIME Oncology.

**Support**   
This educational activity is supported by Millennium: The Takeda Oncology Company and Celgene Corporation.

**Target Audience**   
This activity is intended for practicing hematologists; medical, surgical, and radiation oncologists; and other healthcare professionals interested in and/or involved in the treatment of patients with cancer in the United States.

**Continuing Medical Education**  
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of X.XX *AMA PRA Category 1 Credits****™****.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each module may provide the following credits:

* Myelodysplastic Syndromes: XX
* Multiple Myeloma—Front-Line: XX
* Multiple Myeloma—Relapsed/Refractory: XX
* Non-Hodgkin Lymphoma: XX

**Method of Participation**  
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx).   
  
Links to the posttests are available on the video player pages.

In order to claim credit for these activities, a score of 75% or higher is required on each test.

**Disclosure of Relevant Financial Relationships**  
prIME Oncology assesses relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

**Faculty Disclosures**  
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Anderson has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Czuczman has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Dimopoulos has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Giagounidis has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Jabbour has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lonial has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr San Miguel has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vose has \_\_\_\_\_\_\_. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

* Janice Galleshaw, MD (medical content reviewer/planner) – no relevant financial relationships
* Chelsey Goins, PhD (clinical content reviewer/planner) – no relevant financial relationships
* Briana Betz, PhD (clinical content reviewer/planner) – no relevant financial relationships
* Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

**Disclosure Regarding Unlabeled Use**  
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

**Disclaimer**  
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

**Player Page-Myelodysplastic Syndromes**

**[Insert DCU Graphic header]**

**[INSERT VIDEO]**

**[Buttons- Evaluate and Claim Credit]**

**Activity Information**

**ACTIVITY OVERVIEW**

View a CME-certified expert discussion regarding updates in myelodysplastic syndromes released at the 2014 Annual Hematology Meeting in San Francisco.

**FEATURED EXPERTS**

**Aristoteles Giagounidis, MD, PhD**

St Mary’s Hospital

Duesseldorf, Germany

**Elias Jabbour, MD**

The University of Texas

MD Anderson Cancer Center

Houston, Texas, United States

**FEATURED ABSTRACTS**

**Abstract #163:** Overall Survival and Subgroup Analysis From a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) After Failure of Hypomethylating Agents (HMAs)

**Abstract #409:** Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC Transfusion-Dependent Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) Without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results From a Randomized Phase 3 Study (CC-5013-MDS-005)

**Abstract #534:** Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients With Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy

**SUPPORT STATEMENT**Support for this educational activity is provided by Millennium: The Takeda Oncology Company and Celgene Corporation.

**Player Page-** **Multiple Myeloma: Front-Line**

**[Insert DCU Graphic header]**

**[INSERT VIDEO]**

**[Buttons-Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

View a CME-certified expert discussion regarding updates in front-line multiple myeloma released at the 2014 Annual Hematology Meeting in San Francisco.

**FEATURED EXPERTS**

**Kenneth Anderson, MD**

Dana-Farber Cancer Institute

Boston, Massachusetts

**Jesus San Miguel, MD, PhD**

Universidad de Navarra

Pamplona, Spain

**FEATURED ABSTRACTS**

**Abstract #81:** Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The FIRST Trial

**Abstract #82:** Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) With Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

**Abstract #177:** Response to Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Newly Diagnosed Multiple Myeloma Is Independent of Cytogenetic Risk and Retained After Double Stem Cell Transplant

**SUPPORT STATEMENT**Support for this educational activity is provided by Millennium: The Takeda Oncology Company and Celgene Corporation.

**Player Page-** **Multiple Myeloma: Relapsed/Refractory**

**[Insert DCU Graphic header]**

**[INSERT VIDEO]**

**[Buttons-Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

View a CME-certified expert discussion regarding updates in relapsed/refractory multiple myeloma released at the 2014 Annual Hematology Meeting in San Francisco.

**FEATURED EXPERTS**

**Sagar Lonial, MD**

Emory University

Winship Cancer Center

Atlanta, Georgia, United States

**Meletios Dimopoulos, MD**

University of Athens

Athens, Greece

**FEATURED ABSTRACTS**

**Abstract #79:** Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) With Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study

**Abstract #80:** Safety and Efficacy in the STRATUS (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

**Abstract #302:** Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

**Abstract #304:** Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients With Relapsed Lenalidomide Refractory Multiple Myeloma (MM)

**SUPPORT STATEMENT**Support for this educational activity is provided by Millennium: The Takeda Oncology Company and Celgene Corporation.

**Player Page-** **Non-Hodgkin Lymphoma**

**[Insert DCU Graphic header]**

**[INSERT VIDEO]**

**[Buttons-Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

View a CME-certified expert discussion regarding updates in non-Hodgkin lymphoma released at the 2014 Annual Hematology Meeting in San Francisco.

**FEATURED EXPERTS**

**Julie Vose, MD, MBA**

University of Nebraska Medical Center

Omaha, Nebraska, United States

**Myron Czuczman, MD**

Roswell Park Cancer Institute

Buffalo, New York, United States

**FEATURED ABSTRACTS**

**Abstract #149:** Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

**Abstract #393:** R-CHOP With or Without Radiotherapy in Non-Bulky Limited-Stage Diffuse Large B Cell Lymphoma (DLBCL): Preliminary Results of the Prospective Randomized Phase III 02-03 Trial From the Lysa/Goelams Group

**Abstract #625:** Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report

**Abstract #628:** A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL

**SUPPORT STATEMENT**Support for this educational activity is provided by Millennium: The Takeda Oncology Company and Celgene Corporation.

**Evaluation and Credit Claim Credit Links (will be provided right before launch):**